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Abstract
The Epstein-Barr virus (EBV)-positive subtype of gastric adenocarcinoma is conventionally 
identified by in situ hybridization (ISH) for viral nucleic acids, but next-generation sequencing 
represents a potential alternative. We therefore determined normalized EBV read counts by whole 
genome, whole exome, mRNA and miRNA sequencing for 295 fresh-frozen gastric tumor 
samples. Formalin-fixed, paraffin-embedded tissue sections were retrieved for ISH confirmation of 
13 high-EBV and 11 low-EBV cases. In pairwise comparisons, individual samples were either 
concordantly high or concordantly low by all genomic methods for which data were available. 
Empiric cut-offs of sequencing counts identified 26 (9%) tumors as EBV-positive. EBV-positivity 
or negativity by molecular testing was confirmed by EBER-ISH in all but one tumor evaluated by 
both approaches (kappa=0.91). EBV-positive gastric tumors may be accurately identified by 
quantifying viral sequences in genomic data. Simultaneous analyses of human and viral DNA, 
mRNA and miRNA could streamline tumor profiling for clinical care and research.
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INTRODUCTION
Epstein-Barr virus (EBV) is a recognized carcinogenic agent for several malignancies, 
accounting for about 200,000 new cancer cases annually worldwide.[1] Approximately 9% 
of gastric adenocarcinomas have latent EBV infection in every tumor cell.[2] In viral-
positive tumors, the nucleic acids typically present as monoclonal episomes with uniform 
terminal repeats, indicating infection was present at the time of transformation in the clonal 
progenitor cell.[3] EBV-positive adenocarcinoma cases differ from other gastric cancers, 
exhibiting distinct epidemiological (e.g., male predominance, post-gastrectomy), 
pathological (e.g., preferentially non-antral anatomic subsites) and clinical (e.g., better 
survival) features.[2, 4, 5] Based on a comprehensive molecular analysis of 295 gastric 
adenocarcinomas performed by The Cancer Genome Atlas (TCGA), EBV-positivity was 
identified to mark one of four molecularly distinct subtypes of this disease. EBV-positive 
tumors were characterized by extreme DNA CpG island hypermethylation phenotype 
(CIMP), frequent PIK3CA mutation, absence of TP53 mutation, and recurrent 
amplifications of the chromosome 9 locus containing JAK2, CD274/PD-L1, and 
PDCD1LG2/PD-L2.[6]
EBV is almost ubiquitous in the human population, primarily maintained as a latent 
infection in a subset of B-lymphocytes comprising roughly 10−5 peripheral blood 
mononuclear cells. Detection of EBV in tumor tissue is therefore needed to implicate the 
infection in gastric carcinogenesis. However, the tissue inflammation often present in gastric 
cancer may lead to infiltration of EBV-infected leukocytes as a non-specific source of viral 
sequences. Conventionally, EBV is localized to particular cells within tumor tissue by in situ 
hybridization (ISH) for EBV-encoded small RNA (EBER) types-1 and -2, abundant 
untranslated transcription products of unknown function.[7] This assay is considered to be 
the “gold standard” for assigning EBV status based on its high sensitivity and specificity, as 
long as adequate quantity and integrity of lesional tissue are available.[8] Importantly, in situ 
analyses can determine whether virions are localized within tumor cells or a different tissue 
compartment.
Massive parallel sequencing methodologies offer an alternative approach for detecting 
nucleic acids originating from infectious agents. In the current study, we determine assay 
cut-offs for distinguishing EBV-positive gastric cancer from other molecular subtypes in 
sequencing data from TCGA and evaluate agreement among four genomic technologies as 
well as with conventional EBER-ISH.
METHODS
EBV sequences in nucleic acid extracts of 295 fresh-frozen gastric adenocarcinoma samples 
from TCGA were determined by whole genome (n=77), whole exome (n=263), mRNA 
(n=237) and miRNA (n=293) sequencing and normalized to corresponding human sequence 
counts, as previously reported.[6] Briefly, DNA or RNA sequence reads matching EBV were 
identified by the PathSeq [9] or BioBloom [10] algorithms, respectively. Viral DNA 
abundance was normalized to human sequences by dividing #reads mapped to the microbe 
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by #reads mapped to human in the sample/average # reads mapped to human in the sample 
cohort/4.857, the latter constant representing the ratio of the genome size of EBV to the 
average of all viruses. RNA counts were normalized by millions of total reads sequenced as 
the #reads mapped to the microbe*106/#chastity passed reads. Tumor EBV status was 
provisionally classified based on detection of high or low normalized viral read counts by at 
least two sequencing platforms. All patients provided informed consent, and local 
Institutional Review Boards approved tissue collection.
For comparison to conventional determination of EBV status, we retrieved formalin-fixed, 
paraffin-embedded (FFPE) tissue sections from a matched tumor block for 13 high-EBV 
cases and 11 low-EBV cases selected at random from the same tissue source. EBER-ISH 
was performed at the University of North Carolina. Briefly, three adjacent sections were 
stained by hematoxylin and eosin and by ISH for EBER and for oligodT control RNA to 
confirm RNA integrity, with inclusion of known EBER-positive and -negative tumors as 
external controls. Hybridization was performed using the Leica Bond system with 5 minutes 
of protease digestion and 2 hours of probe hybridization. A tumor was interpreted as EBV-
negative if EBER staining was undetected or only localized to benign-appearing lymphoid 
cells, and EBV-positive if EBER staining was localized to the nucleus of malignant 
epithelial cells, as previously described [11]. Cases with unsatisfactory or indeterminate 
results were re-tested using additional sections from the same block. Histopathologic 
examinations and ISH were performed under code such that laboratory personnel did not 
have access to results of molecular testing.
Relative frequencies of log-transformed EBV read counts were graphed as probability 
density functions using z-scores normalized by subtracting mean counts and dividing by 
standard deviations. Scatterplots were used to compare sample measurements and cutoffs 
selected empirically to optimize concordance across assay platforms. Spearman rank 
correlations between read counts on different platforms were calculated, combined and 
separately for EBV-positive and negative tumors, with p-values less than 0.05 considered 
statistically significant. Sensitivity, specificity and kappa statistics were calculated for 
conventional EBER-ISH as compared to genomic-assigned EBV status. All statistical 
analyses were performed using StataSE v13 (College Station, TX).
RESULTS
By each of the four methods of whole genome, whole exome, mRNA or miRNA massive 
parallel sequencing, numbers of normalized EBV reads across individual samples were 
bimodally distributed, with distinct separation of a minority of tumors having substantially 
higher counts. For each platform, the two modes of log-transformed values were separated 
by approximately three standard deviations (Figure 1).
Pairwise comparisons of the four sequencing platforms indicated that individual samples 
were either consistently high or consistently low by all genomic methods for which data 
were available. Log-log scatterplots of the 295 TCGA samples were confined to upper right 
and lower left quadrants only (Figure 2).
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Overall quantitative counts were moderately correlated (all p-values < .001), with Spearman 
rank correlation coefficients (Rho) ranging from 0.2 to 0.8 (Table 1). Stratified by EBV 
status, counts were less correlated. Among EBV-positive tumors, the only significant 
correlation among the four genomic platforms was between miRNA and mRNA (rho=0.6). 
Among EBV-negative tumors, four of the six pairwise correlations were significant, with 
higher correlation between mRNA and whole genome (rho=0.6) and lower correlations for 
the other three comparisons (rho<0.3).
By comparing distributions of the genomic data, empiric cut-offs were defined as 1000 
normalized EBV reads for whole genome sequencing, 100 for exome, 4 for mRNA, and 
5000 for miRNA for perfect concordance in identifying 26 (9%) EBV-positive samples 
among the 295 TCGA tumors analyzed (Table 2).
In blinded evaluations of 24 gastric cancer tissues, 13 cases exhibited distinct EBER 
localization to tumor cells (Figure 3); initial assay results were equivocal for a fourteenth 
case that on re-testing was classified as EBER-positive with some background staining. Nine 
tumors were clearly EBER-ISH negative. One case was unclassifiable because sampled fixed 
tissue did not contain any tumor cells in two separately evaluated sections.
For the 23 tumors with EBV status determined by both genomic and conventional 
approaches, agreement was observed in all but one case (Figure 2). The sole exception was 
the tumor with initially equivocal EBER-ISH results, reclassified as positive; this case was 
EBV-negative by both mRNA and miRNA sequencing and was classified as microsatellite 
instability-type gastric cancer by DNA methylation and other genomic data. Assuming 
greater accuracy of the molecular assignments, EBER-ISH was 100% sensitive and 90% 
specific with a kappa statistic of 0.91, representing 96% observed agreement between 
conventional and molecular assignment of EBV status.
DISCUSSION
The current study capitalizes on TCGA data on a large set of gastric cancer specimens 
collected under standardized conditions with detailed annotation, and subjected to multiple 
analytical platforms. Four different next-generation sequencing methods had perfect 
concordance classifying EBV status for gastric cancer tissues. The accepted standard 
technique of EBER-ISH had excellent agreement to the genomic classification, with one 
presumed false-positive in the presence of background hybridization.
Our data suggest that next generation sequencing platforms may provide an accurate 
replacement for conventional ISH. However, there are several potential hurdles to practical 
implementation for routine use. Quantitation of viral sequences may vary due to differences 
in specimen processing, assay protocols and inherent batch-to-batch fluctuation.[12] The 
specific cut-offs generated for this sample set may not be applicable to other cases and 
testing laboratories need to determine their own criteria for establishing EBV-positivity. 
Furthermore, these excellent genomic results were obtained on frozen tissues of optimal 
nucleic acid quality; replication is needed on a wider variety of sample types, including fixed 
tissues.
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The robust detectability of EBV by whole exome sequencing was unexpected. Our target 
enrichment platform (Agilent SureSelect Human All Exon) utilized 120-nucleotide RNA 
baits designed to capture all human exons with relative exclusion of other DNA sequences. 
Nevertheless, there were sufficient off-target reads to detect at least some portion of the viral 
genome in every EBV-positive gastric tumor. An alternative strategy pursued for TCGA 
analysis of esophageal cancer is to supplement the exome capture library with 120-mer 
probes specifically designed to cover cancer-related viruses, based on spacing, GC-content, 
repeat content and lack of similarity to human sequence (Michael McLellan, personal 
communication).
EBV-positive gastric cancer tissues have much higher levels of viral miRNA as compared to 
EBV-negative tumors.[13] Viral-derived miRNAs may also be detected in various body 
fluids[14] and levels in blood plasma have been evaluated as diagnostic and prognostic 
markers for nasopharyngeal carcinoma, the second most frequent EBV-associated 
malignancy.[15, 16] Circulating blood levels of EBV miRNA warrant investigation as a 
potential non-invasive test for EBV-positive gastric cancer when tumor tissue is inadequate 
or unavailable for direct assessment.
EBV-positive gastric cancers exhibit a restricted transcription pattern of viral genes, with 
most of the highly expressed sequences encoded in the BamH1A gene region of the genome.
[6, 17] These transcripts and their protein products are candidate targets for functional 
studies to explore mechanisms of viral carcinogenesis. Elucidating the viral contribution to 
gastric cancer pathophysiology could lead to novel strategies for prevention and treatment, 
with possible extension to other EBV-related malignancies.
The recognition of EBV-positive gastric cancer as a distinct entity has informed scientific 
understanding of gastric carcinogenesis. Increasing availability of massive parallel 
sequencing will facilitate routine identification of these tumors for clinical translation of 
important research findings.
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Figure 1. 
Probability density plots of normalized EBV read counts in gastric cancer tissues by whole 
genome (WGS; n=77), exome (n=263), mRNA (n=237) and miRNA (n=293) sequencing.
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Figure 2. 
Pairwise comparisons of normalized EBV read counts in gastric cancer tissues by whole 
genome (WGS), exome, mRNA and miRNA sequencing. Solid circles represent EBER-
positive tumors (n=14), open circles represent EBER-negative tumors (n=9) and dots 
indicate TCGA tumors not tested by in situ hybridization (n=272).
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Figure 3. 
Representative photomicrographs of an EBV-positive gastric cancer tumor stained with 
hematoxylin and eosin (left panel), EBER-ISH (center panel) and RNA preservation control 
(right panel).
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